Mineralocorticoid receptor antagonists

@article{Parthasarathy2007MineralocorticoidRA,
  title={Mineralocorticoid receptor antagonists},
  author={Hari K. Parthasarathy and Thomas M MacDonald},
  journal={Current Hypertension Reports},
  year={2007},
  volume={9},
  pages={45-52}
}
With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of mineralocorticoid receptor antagonists has provided clinicians with an important tool towards complete blockade of the reninangiotensin… Expand
Role of mineralocorticoid receptor antagonists in kidney diseases
TLDR
It appears that the nonsteroidal MRAs can provide optimum therapeutic benefit for patients suffering from kidney diseases and are less likely to cause hyperkalemia at therapeutic doses. Expand
Advances in the Development of Non-steroidal Mineralocorticoid-receptor Antagonists
TLDR
The structure-activity relationships of known ligands, together with the insights provided by the 3D structures of ligand LBD MR complexes, could help in the development of non-steroidal MR antagonists with improved properties. Expand
Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure.
TLDR
Positive effects of spironolactone on morbidity and mortality appear to have been seen in studies conducted in dogs suffering from naturally occurring CHF, and eplerenone has been shown to have benefits in canine models of heart failure. Expand
Corticosteroids and circadian rhythms in the cardiovascular system.
TLDR
The role of the mineralocorticoid receptor and its ligands in the regulation of the circadian clock in the heart and the implications of dysregulation of these systems for cardiac disease progression, and for MR activation are discussed. Expand
Crystal structure of the mineralocorticoid receptor ligand‐binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS‐3150)
TLDR
It is found that esaxerenone binds to MR‐LBD in a unique manner with large side‐chain rearrangements, distinct from those of previously published MR antagonists, providing great insight into the novelty, potency, and selectivity of this novel antihypertensive drug. Expand
Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders
TLDR
The research progress on drugs for GLMD is reviewed and the direction for exploring new drugs to treat GLMD by taking the HPA axis as the target is provided to improve the level of prevention and control of GLMD. Expand
Increased SGK1 activity potentiates mineralocorticoid/NaCl-induced hypertension and kidney injury
TLDR
It is proposed that systemically increased SGK1 activity is a risk factor for the development of mineralocorticoid-dependent hypertension and incipient kidney injury in the context of low renal mass. Expand
Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19?
TLDR
The evidence that spironolactone may be the preferred RASSi to increase PN1 and decrease TMPRSS2, furin and plasmin activities and thereby to reduce viral cell binding, entry, infectivity and bad outcomes is reviewed. Expand
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism
TLDR
The antihypertensive effect of spironolactone was significantly greater than that of eplerenone in hypertension associated with primary aldosteronism. Expand
Hypertension Drug Therapy.
  • R. Hui
  • Medicine
  • Advances in experimental medicine and biology
  • 2020
TLDR
This reviewer studied comprehensively the literature, hopefully that the review will help improve antihypertensive drug selection and anti Hypertensive therapy. Expand
...
1
2
...